GNBT,
Generex Biotechnology Announces U.S. Distribution of New Glucose Rapidspray(TM) Product
Monday September 18, 9:50 am ET
TORONTO--(MARKET WIRE)--Sep 18, 2006 -- Generex Biotechnology Corporation (NASDAQ:GNBT - News), the leader in metabolic diseases drug delivery through the inner lining of the mouth, announced today that Cardinal Health will distribute its new Glucose RapidSpray(TM) product in the U.S.
ADVERTISEMENT
Glucose RapidSpray is expected to be in stores by October, 2006.
Glucose RapidSpray is an innovative alternative for people who require or want additional glucose in their diet. Glucose RapidSpray delivers a fat-free, low-calorie glucose formulation that was developed using the Company's proprietary buccal drug delivery technologies. Glucose RapidSpray delivers glucose directly into the mouth where the proprietary formulation is rapidly absorbed into the blood stream. Glucose RapidSpray is simple to carry and use, with no large tablets to chew or messy gels to swallow.
"Using our patented technology -- RapidMist(TM) -- we've developed a product that will deliver glucose to anyone who needs a fast and efficient means for receiving glucose," said Anna Gluskin, President & Chief Executive Officer of Generex. "We expect that Glucose RapidSpray will appeal to people battling the symptoms of low blood sugar who now use other over-the-counter glucose products but want a faster-acting product. We expect to position Glucose RapidSpray as a companion product to Generex Oral-lyn(TM), our proprietary oral insulin spray product, in the diabetes management field." |
